Dato DXd (ADC) Approved by U.S. FDA for Lung Cancer
Dato DXd (datopotamab deruxtecan) has received U.S. FDA approval – a breakthrough milestone announced jointly by Daiichi Sankyo and AstraZeneca on June 23, 2025. The drug is indicated for the treatment of adults with locally…